Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates. https://t.co/KVBReCMjcd

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®. https://t.co/L6NVhxfyx3

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate. https://t.co/sFyJGRARiW

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates. https://t.co/VA8YAeS2tQ

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly. https://t.co/2ZLONMncTT

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus. https://t.co/fKufGZIEr3

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance. https://t.co/9CzTGtKTvx

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®. https://t.co/dtKxhxwCSO

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update. https://t.co/rMWB2yFjwW

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates. https://t.co/ltlEbAgy2g

It’s the last day of the World Vaccine Congress. Don’t miss our Chief Medical Officer, Juan Carlos Jaramillo’s panel discussion addressing the importance of vaccines against mosquito borne diseases. You can also visit us at booth #424 to learn more about our work! #WVCUSA

Today at the World Vaccine Congress our VP of Clinical Development, Susanne Eder-Lingelbach will be sharing vital insights into our chikungunya vaccine. Find us in Room 202B for her presentation. #WVCUSA

Today at the World Vaccine Congress, our Chief Scientific Officer, Dr Hanneke Schuitemaker will be leading a working group focused on on Prophylactic Enteric Disease Vaccines. You can also find our team at booth #424 - we hope to see you there! #WVCUSA

Join us at World Vaccine Congress 2025! We are delighted that three members of the Valneva team will be sharing their knowledge at various events over the next few days. You can also visit us at booth #424. Read our press release here: https://t.co/DbCFcGyvLM #WVCUSA

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country. https://t.co/LoZoevkiEE

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2. https://t.co/K1PBWxDdyy

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and above. https://t.co/BzAAfJHQeO

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA. https://t.co/XPl5AoQDDB

We're excited to launch our Annual Business Report website! The website provides insight into Valneva’s mission, financial outlook and serves as a hub for our 2024 annual results resources. To find out more, visit: https://t.co/5CyAssLa5z #AdvancingVaccinesForBetterLives

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F. https://t.co/YQQrTPSBAJ